
Ask a doctor about a prescription for PANTOPRAZOL REIWA HEALTHCARE 40 mg POWDER FOR INJECTABLE SOLUTION
Pantoprazole Reiwa Healthcare 40 mg powder for solution for injection EFG
Pantoprazole
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
5 Storage of Pantoprazole Reiwa Healthcare
Pantoprazole Reiwa Healthcare contains the active substance pantoprazole.
Pantoprazole Reiwa Healthcare is a selective inhibitor of the "proton pump", a medicine that reduces the amount of acid produced in your stomach. It is used for the treatment of diseases related to stomach and intestine acid. This medicine is injected into a vein and will only be administered to you if your doctor considers that the injection of pantoprazole, at this time, is more convenient for you than pantoprazole tablets. The tablets will replace the injections as soon as your doctor considers it appropriate.
Pantoprazole Reiwa Healthcare is used for the treatment of:
Do not use Pantoprazole Reiwa Healthcare
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before starting to use Pantoprazole Reiwa Healthcare:
Tell your doctor immediately,before or after taking this medicine, if you notice any of the following symptoms, which may be signs of more serious diseases:
Your doctor will decide if you need any additional tests to rule out a malignant disease because pantoprazole can alleviate the symptoms of cancer and may delay its diagnosis. If, despite treatment, your symptoms persist, complementary tests will be performed.
Children and adolescents
The use of Pantoprazole Reiwa Healthcare is not recommended in children as it has not been tested in children under 18 years of age.
Other medicines and Pantoprazole Reiwa Healthcare
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription.
Pantoprazole Reiwa Healthcare may affect the effectiveness of other medicines, tell your doctor if you are taking:
Pregnancy and breastfeeding
There is not enough data on the use of pantoprazole in pregnant women. It has been reported that in humans, pantoprazole is excreted in breast milk.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
You should only use this medicine if your doctor considers that the benefit to you is greater than the potential risk to the fetus or baby.
Driving and using machines
Pantoprazole Reiwa Healthcare has no influence or negligible influence on the ability to drive or use machines.
You should not drive or use machines if you experience side effects such as dizziness or blurred vision.
Pantoprazole Reiwa Healthcare contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per vial; it is essentially "sodium-free".
Your nurse or doctor will administer the daily dose as an injection into a vein over a period of 2-15 minutes.
The recommended dose is:
Adults
For the treatment of gastric ulcers, duodenal ulcers, and reflux esophagitis.
One vial (40 mg of pantoprazole) per day.
For long-term treatment of Zollinger-Ellison syndrome and other conditions in which there is an increase in stomach acid secretion.
Two vials (80 mg of pantoprazole) per day.
Subsequently, your doctor may adjust the dose, depending on the amount of acid secretion you produce. If you are prescribed more than two vials (80 mg) per day, the injections will be administered in equal doses. Your doctor may prescribe a dose of more than four vials (160 mg) per day temporarily. If you need to quickly control your stomach acid levels, an initial dose of 160 mg (four vials) should be sufficient to significantly reduce stomach acid.
Patients with liver problems
Use in children and adolescents
If you use more Pantoprazole Reiwa Healthcare than you should
This medicine is controlled with caution by your nurse or doctor, so it is very unlikely that you will receive more than you should.
There are no known symptoms of overdose.
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or nurse immediately, or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount ingested.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any of the following side effects, tell your doctor immediately:
Other side effects are:
Inflammation of the vein wall and blood clots (thrombophlebitis) at the injection site, benign polyps in the stomach.
Headache; dizziness; diarrhea; feeling of dizziness, vomiting; swelling and bloating (gas); constipation; dry mouth; abdominal pain and discomfort; skin rash, exanthema, eruption; tingling; feeling of weakness, fatigue, or general malaise; sleep disturbances; hip, wrist, and spine fractures.
Alteration or complete loss of taste; vision disturbances such as blurred vision; hives; joint pain; muscle pain; weight changes; increased body temperature; high fever; swelling in the limbs (peripheral edema); allergic reactions; depression; breast enlargement in men.
Disorientation
Hallucinations, confusion (especially in patients with a history of these symptoms), decreased sodium levels in the blood, decreased magnesium levels in the blood (see section 2), tingling, prickling, paresthesia (tingling), burning, or numbness, skin rash, possibly with joint pain, inflammation of the large intestine that causes persistent watery diarrhea.
Side effects identified through blood tests:
Increased liver enzymes
Increased bilirubin; increased fat in the blood; sudden drop in white blood cell count, associated with high fever.
Reduction in platelet count, which may cause bleeding or more bruising than usual; reduction in white blood cell count, which may lead to more frequent infections; abnormal reduction in the balance between red and white blood cell count, as well as platelets.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date that appears on the packaging after EXP. The expiry date is the last day of the month indicated.
Store the vial in the original packaging.
After reconstitution, or reconstitution and dilution with diluents, they are stable for 12 hours at 15°C-25°C.
Discard unused contents.
Medicines should not be disposed of via wastewater or household waste. If in doubt, ask your pharmacist how to dispose of the packaging and medicines that are no longer needed. This will help protect the environment.
Composition of Pantoprazole Reiwa Healthcare
Appearance of the product and packaging of Pantoprazole Reiwa Healthcare
Pantoprazole Reiwa Healthcare is a white or off-white lyophilized powder for solution for injection. It is presented in a 10 ml transparent glass vial with a gray rubber stopper and closed with a flip-off aluminum cap.
Pantoprazole Reiwa Healthcare is available in the following pack sizes:
Pack with 10 vials.
Marketing authorization holder and manufacturer
Marketing authorization holder
Reiwa Healthcare S.L.
Carretera de Fuencarral, 22
28108 – Alcobendas
Madrid
Spain
Manufacturer
Netpharmalab Consulting Services S.L.
Carretera de Fuencarral, 22
28108 – Alcobendas
Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Hungary: Pantoprazol Reiwa Healthcare 40 mg por oldatos injekcióhoz
Portugal: Pantoprazol Reiwa Healthcare 40mg Pó para solução injetável
Spain: Pantoprazol Reiwa Healthcare 40 mg polvo para solución inyectable EFG
Date of the last revision of this leaflet:09/2024
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
This information is intended only for healthcare professionals:
The solution for immediate use is prepared by injecting 10 ml of 9 mg/ml (0.9%) sodium chloride solution into the vial containing the powder. This solution can be administered directly or diluted in 100 ml of 9 mg/ml (0.9%) sodium chloride solution or 5% glucose solution for injection or 55 mg/ml (5%) glucose solution for injection. For dilution, glass or plastic containers should be used.
Pantoprazole Reiwa Healthcare should not be prepared or mixed with solvents other than those specified.
After reconstitution, the solution can be used within the next 12 hours. If not, storage within the time and conditions of use is the responsibility of the user and should not normally exceed 12 hours and 25°C.
The medicine will be administered intravenously over 2-15 minutes.
Any remaining product in the vial or any vial in which a change in appearance is detected (e.g., if turbidity or precipitation is observed) should be discarded.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for PANTOPRAZOL REIWA HEALTHCARE 40 mg POWDER FOR INJECTABLE SOLUTION – subject to medical assessment and local rules.